Becton, Dickinson and Company (BDX) is a Medical - Instruments & Supplies company in the Healthcare sector, currently trading at $155.73. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of BDX = $318.86 (+104.8% from the current price, the stock appears undervalued). Analyst consensus target is BDX = $194 (+24.4% upside).
Valuation: BDX trades at a trailing Price-to-Earnings (P/E) of 25.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 3.41.
Financials: revenue is $21.8B, +5%/yr average growth. Net income is $1.7B, growing at -1.1%/yr. Net profit margin is 7.7% (thin). Gross margin is 45.4% (+0.5 pp trend).
Balance sheet: total debt is $19.2B against $25.4B equity (Debt-to-Equity (D/E) ratio 0.76, moderate). Current ratio is 1.11 (adequate). Debt-to-assets is 34.7%. Total assets: $55.3B.
Analyst outlook: 16 / 33 analysts rate BDX as buy (48%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 36/100 (Fail), Growth 40/100 (Partial), Past 100/100 (Pass), Health 50/100 (Partial), Moat 73/100 (Pass), Future 46/100 (Partial), Income 45/100 (Partial).
